Galux, a South Korean biotech doing research on AI-driven protein therapeutics discovery, entered into a research agreement with Boehringer Ingelheim to jointly explore the application of artificial intelligence (AI) in precision protein design for therapeutic development. The goal is to evaluate how AI can be leveraged to design purpose-specific protein molecules that meet precise scientific and translational needs, where conventional approaches face limitations.
“Through this agreement, we aim to explore how AI protein design can address highly specific scientific and translational needs. These are challenges that often require precise and tailored molecular solutions,” said Chaok Seok, CEO of Galux. “It’s about demonstrating that AI can move beyond prediction to purposeful molecular design, creating proteins that meet clearly defined research and therapeutic goals.”
Earlier this year, Galux reported that it has reached a major milestone in de novo antibody design, successfully discovering novel antibodies with high binding affinity, target specificity and selectivity, structural precision, and stability across multiple therapeutic targets. Building on this achievement, the initial phase of the collaboration will focus on validating the feasibility and potential of AI-driven protein design across selected cases, setting the stage for broader research initiatives between the two companies.
“At Galux, we believe the future of therapeutics lies in precise design,” continued Seok. “This is an important step toward realizing that vision, bringing together the precision of AI and the depth of biomedical science to unlock new therapeutic possibilities.”
